NextCure, Inc. (NXTC) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. NextCure, Inc. is a clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs) for cancer treatment. The company has no product revenue and has historically funded operations through equity financing. As of the filing date, NextCure operates as a standalone entity but has entered into a definitive merger agreement with Avere Therapeutics, Inc., announced on July 14, 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(14.9) million | $(24.7) million | $(37.8) million |
| Loss Per Share (Basic/Diluted) | $(2.80) | $(4.68) | $(16.05) |
| Operating Expenses | $15.1 million | $25.2 million | $38.9 million |
| Cash & Cash Equivalents | $15.3 million | $15.3 million (End of Period) | $4.9 million (End of Period) |
| Marketable Securities | $4.8 million | $4.8 million (End of Period) | $15.8 million (End of Period) |
| Total Liquidity | $20.1 million (Cash + Marketable Securities) | ||
| Accumulated Deficit | $(460.7) million |
Material Changes vs. Prior Period
- Significant Expense Reduction: Net loss decreased by approximately $13.1 million year-over-year for the six-month period. This improvement is primarily driven by a $17.0 million license fee paid to Simcere Zaiming Pharmaceutical Co., Ltd. in Q2 2025, which did not recur in 2026.
- Asset Impairment: The company recorded a non-cash asset impairment charge of $5.1 million in Q2 2026 related to right-of-use assets and property/equipment, driven by a decline in stock price and the decision to restructure operations pending the merger. No such charge existed in the prior year.
- Liquidity Position: Total cash and marketable securities decreased from $41.8 million at year-end 2025 to $20.1 million at June 30, 2026, due to operating cash burn and the sale of marketable securities.
- Share Count: Weighted average shares outstanding increased significantly due to the exercise of pre-funded warrants (456,855 shares in Q2) and at-the-market (ATM) sales.
Guidance, Outlook, and Risks
- Merger with Avere Therapeutics: On July 14, 2026, NextCure agreed to merge with Avere Therapeutics. The combined entity will trade as "AVRX." NextCure shareholders will receive contingent value rights (CVRs) tied to the monetization of legacy assets. The merger is subject to stockholder approval and closing conditions.
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for one year following the report date, absent the completion of the merger or additional financing. Current liquidity is projected to fund operations only into the fourth quarter of 2026.
- Restructuring: A workforce reduction plan was approved in July 2026, expected to incur approximately $2.4 million in one-time charges (severance, etc.) primarily in Q3 2026. This includes a substantial reduction of the workforce.
- Program Wind-down:
- SIM0505: The company halted enrollment of new patients in the U.S. Phase 1 trial and ceased expansion plans for Europe/Canada. It is seeking to partner or monetize the asset.
- LNCB74: NextCure opted out of cost-sharing with LigaChem. LigaChem will assume 100% of development costs effective July 1, 2026, with NextCure retaining rights to milestones and royalties.
- Lease Termination: Subsequent to quarter-end, the company terminated leases for approximately 39,432 square feet of space, incurring a one-time fee of $0.8 million.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of stockholder approvals and the concurrent $320 million private placement financing for Avere Therapeutics, which is a condition to the merger closing.
- Liquidity Runway: Confirm the company's cash burn rate and ability to fund operations through Q4 2026 if the merger is delayed or terminated.
- Asset Monetization: Assess the likelihood and timeline for monetizing legacy assets (SIM0505, LNCB74) to generate value for the Contingent Value Rights (CVRs).
- Restructuring Costs: Monitor the actual recognition of the estimated $2.4 million restructuring charges and any additional transaction costs in Q3 and Q4 2026.
- Lease Obligations: Review the impact of the lease amendments and the $0.8 million termination fee on future cash flows.